abrdn Healthcare Investors (NYSE:HQH) Sets New 12-Month High – What’s Next?

abrdn Healthcare Investors (NYSE:HQH) hit a new 52-week high on Monday . The stock traded as high as $21.91 and last traded at $21.84, with a volume of 75456 shares changing hands. The stock had previously closed at $21.63.

abrdn Healthcare Investors Price Performance

The stock has a 50-day simple moving average of $19.77 and a 200-day simple moving average of $19.22.

abrdn Healthcare Investors Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 30th. Investors of record on Thursday, May 21st will be issued a $0.61 dividend. The ex-dividend date of this dividend is Thursday, May 21st. This represents a $2.44 annualized dividend and a yield of 11.1%.

Institutional Investors Weigh In On abrdn Healthcare Investors

Several institutional investors have recently added to or reduced their stakes in HQH. Bollard Group LLC bought a new position in abrdn Healthcare Investors during the first quarter worth about $25,000. Geneos Wealth Management Inc. increased its stake in shares of abrdn Healthcare Investors by 9,232.3% in the second quarter. Geneos Wealth Management Inc. now owns 2,893 shares of the financial services provider’s stock worth $45,000 after purchasing an additional 2,862 shares in the last quarter. Flagship Harbor Advisors LLC bought a new stake in shares of abrdn Healthcare Investors in the fourth quarter valued at approximately $48,000. Advisory Services Network LLC bought a new position in abrdn Healthcare Investors in the 3rd quarter worth approximately $97,000. Finally, Global Retirement Partners LLC purchased a new position in abrdn Healthcare Investors in the 4th quarter valued at approximately $106,000. 32.60% of the stock is owned by hedge funds and other institutional investors.

About abrdn Healthcare Investors

abrdn Healthcare Investors (NYSE:HQH) is a closed-end management investment company that seeks long-term capital appreciation and current income by investing primarily in equity securities of companies operating in the healthcare sector. The fund’s portfolio generally comprises a diversified mix of domestic and international healthcare issuers, spanning pharmaceuticals, biotechnology, medical devices, healthcare services, and related industries.

The fund employs a fundamental, research-driven approach to select investments, focusing on companies with strong balance sheets, innovative product pipelines and the potential for sustainable revenue growth.